Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: A comparative study in humans versus low molecular weight heparin

Thrombosis and Haemostasis

Volumn 88, Issue 5, 2002, Pages 733-738

  Shimbo, Daichi ^a   Osende, Julio ^a   Chen, Julie ^a   Robbins, Jonathan ^a   Shimoto, Yoshimasa ^a   Kunitada, Satoshi ^a   Fuster, Valentin ^a   Badimon, Juan Jose ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Coagulation; Plaque; Thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBOPLASTIN; FIBRINOLYTIC AGENT; NAPHTHALENE DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING PARAMETERS; BOLUS INJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PERFUSION; PRIORITY JOURNAL; PROTHROMBIN TIME; SHEAR RATE; THROMBOSIS; THROMBUS; ADULT; BLOOD; BLOOD CLOTTING TEST; BLOOD RHEOLOGY; DRUG ANTAGONISM; DRUG COMBINATION; HEMOSTASIS; MECHANICAL STRESS; MIDDLE AGED;

ADULT; ASPIRIN; BLOOD COAGULATION TESTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ENOXAPARIN; FACTOR XA; FIBRINOLYTIC AGENTS; HEMORHEOLOGY; HEMOSTASIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PROPIONIC ACIDS; STRESS, MECHANICAL;

EID: 0036847576     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613294     Document Type: Article

References (26)

1. Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000; 149: 251-66.
2. Cairns JA, Theroux P, Lewis HD, Jr., Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest 2001; 119: 228S-252S.
3. Fuster V, Fayad ZA, Badimon J.J. Acute coronary syndromes: biology. Lancet 1999; 353 (Suppl 2): SII5-SII9.
4. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
5. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
6. Kaikita K, Ogawa H, Yasue H, Takeya M, Takahashi K, Saito T, Hayasaki K, Horiuchi K, Takizawa A, Kamikubo Y, Nakamura S. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 1997; 17: 2232-7.
7. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
8. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
9. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT. Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
10. Giesen PL, Fyfe BS, Fallon JT, Roque M, Mendlowitz M, Rossikhina M, Guha A, Badimon JJ, Nemerson Y, Taubman MB. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost 2000; 83; 622-8.
11. Lev EI, Marmur JD, Zdravkovic M, Osende JI, Robbins J, Delfin JA, Richard M, Erhardtsen E, Thomsen MS, Lincoff AM, Badimon JJ. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Arterioscler Thromb Vasc Biol 2002; 22: 1036-41.
12. Lincoff AM. First clinic investigation of TF inhibition administered during percutaneous revascularization: a randomized double-blinded, dose-escalating trial: assessing safety and efficacy of FFR: vFVIIa in PTCA. JACC 2000; 36: 312-3 (A).
13. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25.
14. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ, Van de Werf F. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001; 22: 1716-24.
15. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9.
16. Herault JP, Perrin B, Jongbloet C, Pflieger AM, Bernat A, Herbert JM. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats. Thromb Haemost 2000; 84: 668-74.
17. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 392-6.
18. Rogers KL, Chi L, Rapundalo ST, Kramer JB, Gallagher KP. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis. Basic Res Cardiol 1999; 94: 15-22.
19. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
20. Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI, Farkouh ME, Fuster V, Badimon JJ, Chesebro J.H. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000; 20: 2316-21.
21. Hayes R, Chesebro JH, Fuster V, Dangas G, Fallon JT, Sharma SK, Coller BS, Badimon L, Marmur JD, Badimon JJ. Antithrombotic effects of abciximab. Am J Cardiol 2000; 85: 1167-72.
22. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8.
23. Turpie AG, Antman EM. Low-molecular-weight heparins in the treatment of acute coronary syndromes. Arch Intern Med 2001; 161: 1484-90.
24. Roque M, Rauch U, Reis ED, Chesebro JH, Fuster V, Badimon JJ. Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury. Thromb Res 2000; 98: 499-505.
25. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-91.
26. Leadley RJ, Jr., Chi L, Porcari AR. Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr Opin Pharmacol 2001; 1: 169-75.